Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer
Status:
Unknown status
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
It is hypothesized that other anti-angiogenic agents such as endostar, may augment the effect
of chemotherapy regimens in CRC. Endostar, a recombinant human endostatin which expressed and
purified in E. coli, was approved by the SFDA for the treatment of non-small-cell lung cancer
in 2005. Ling et al. found that endostar suppressed the VEGF-stimulated proliferation,
migration, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro,
and the antiangiogenic effects of endostar were correlated with the VEGF-triggered signaling.
(Ling et al, 2007) A Chinese phase III clinical trial in advanced non-small-cell lung cancer,
endostar--a new angiogenesis inhibitor prolonged the overall survival, time to progression
and improved response rate. (Wang et al, 2005) Based on these results, the investigators
design this phase II clinical trial of oxaliplatin, capecitabine and endostar as first line
treatment, to evaluate whether endostar can bring survival benefits to patients with advanced
colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Treatments:
Capecitabine Endostar protein Endostatins Oxaliplatin